Kornimate/medical-research-clean huggingface dataset:
3tc or no 3tc for hiv with 3tc resistance

Conditions: HIV Infections

Summary: the purpose of this study is to compare the effects of continuing or discontinuing 3tc treatment in the presence of hiv virus with 3tc resistance for persons who are on a regimen including least three other anti-hiv drugs. the overall aim is to determine whether continuing 3tc is of benefit in hiv-positive persons who have already shown resistance to this drug.


Eligibility criteria:
inclusion criteria: * be hiv positive * be at least 18 years old. * currently receiving 3tc for hiv infection in conjunction with at least three other antiretroviral drugs. must have started this regimen at least three months prior to starting this study. * a plasma viral load of less than 50 copies/ml on at least two occasions (measured at least 28 days apart immediately prior to screening). * evidence of resistance to 3tc exclusion criteria: * pregnancy or breastfeeding. * hepatitis b surface antigen (hbsag) positive at time of screening or with the previous year.

Keywords: hiv treatment experienced
a study of askg712 in patients with diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: this multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion study will investigate the safety, tolerability, pharmacokinetics and efficacy of askg712 following intravitreal administration in patients with diabetic macular edema (dme).

the part 1 of study is a multicenter, open-label, sequentially, multiple-dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of askg712 in patients with dme. patients will be sequentially enrolled into four different dose-level cohorts following accelerated titration combined with the traditional "3+3" design. the part 2 of study is a multicenter, open-label, sequentially, dose-expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of askg712 in patients with dme.

Eligibility criteria:
inclusion criteria: 1. documented diagnosis of diabetes mellitus (type 1 or type 2) 2. hemoglobin a1c of less than or equal to 12% 3. for women of childbearing potential: agreement to use acceptable contraceptive methods during the treatment period and for at least 90 days after the final dose of study treatment 4. ability and willingness to undertake all scheduled visits and assessments 5. macular thickening secondary to dme involving the center of the fovea 6. decreased visual acuity attributable primarily to dme exclusion criteria: 1. history of allergy or current allergic response to askg712 or fluorescein 2. diseases that affect intravenous injection and venous blood sampling 3. uncontrolled blood pressure 4. systemic autoimmune diseases 5. previous anti-vegf drug treatment 6. currently pregnant or breastfeeding, or intend to become pregnant during the study 7. any uncontrolled clinical disorders 8. any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than dme in the study eye 9. history of intraocular or periocular corticosteroid treatment in the study eye 10. uncontrolled previous or current glaucoma in the study eye 11. previous intraocular operations in the study eye 12. active intraocular or periocular infection or active intraocular inflammation in the study eye 13. history of uveitis in either eye 14. other protocol-specified inclusion/exclusion criteria may apply
comparison of different gfr measurements in chronic kidney diseases

Conditions: Chronic Kidney Diseases

Summary: comparison of different gfr measurements in chronic kidney diseases

comparison of gfr measured by different method as radionuclide method and creatinine clearance

Eligibility criteria:
inclusion criteria: * patients with proven or suspected ckd who will be referred to nuclear medicine departement of assuit university hospital and will undergo dynamic renal imaging. exclusion criteria: * severely ill patients * disturbed conscious level * patients on dialysis * patients have oedema or ascites
chinese picu collaborative network on pathogens and drug resistance of severe infections

Conditions: Severe Infection

Summary: to investigate picus in major cities in china by establishing a high-quality standardized clinical database of picu inpatients incidence, fatality rate, pathogen distribution, anti-infective treatment of community-acquired/nosocomial infections in inpatients.

all patients admitted to the picu during january 1, 2016 to december 31 2025 were included in the study, and all patients were followed up until death or picu withdrawal. to establish the standardized access database collected patients' general information, infection, picu treatment, catheter, and short-term prognosis and other clinical data.

Eligibility criteria:
inclusion criteria: * picu patients with severe infection exclusion criteria: * non-infected patient

Keywords: picu pathogen severs infection drug resistance
interactive computer program or brochure in increasing colorectal cancer screening among african americans

Conditions: Colorectal Cancer

Summary: rationale: an interactive computer program may be more effective than a brochure in increasing colorectal cancer screening among african americans. purpose: this randomized clinical trial is studying an interactive computer program to see how well it works compared with a brochure in increasing colorectal cancer screening among african americans.

objectives: * compare rates of participation in fecal occult blood testing and endoscopic screening (colonoscopy or sigmoidoscopy) among african-americans who receive an interactive computer intervention (ici) versus a non-tailored colorectal cancer screening brochure. * examine mediators and moderators of intervention effectiveness as depicted in the conceptual model. outline: this is a multicenter study. participants are stratified according to site, age (≤ 65 years old vs \> 65 years old) and gender. participants are randomized to one of two arms. * arm i (non-tailored colorectal cancer screening brochure): participants undergo a baseline interview via telephone and receive a colorectal cancer screening brochure in the clinic prior to visit with healthcare provider. participants then undergo telephone interviews at 1 week, 6 months, and 15 months. * arm ii (interactive computer intervention \[ici\]): participants undergo a baseline interview via telephone and complete an ici in the clinic prior to visit with healthcare provider. participants then undergo telephone interviews at 1 week, 6 months, and 15 months.

Eligibility criteria:
disease characteristics: * currently being seen in the primary care clinics of wishard memorial hospital (indianapolis, in), roudebush veterans affairs medical center (indianapolis, in), iu health family medicine center (indianapolis, in) or norton louisville primary care clinic (louisville, ky) * african-american who is currently non-adherent to screening guidelines, meeting all of the following criteria: * no fecal occult blood test in the past 12 months * no sigmoidoscopy in the past 5 years * no colonoscopy in the past 10 years * patients with average and increased risk for colorectal cancer are eligible * no personal history of colorectal cancer patient characteristics: * participants must have a telephone * english-speaking * able to read at a 5th grade reading level * no medical condition that prohibits colorectal cancer screening prior concurrent therapy: * see disease characteristics

Keywords: colon cancer rectal cancer
diagnostic performances of urine and plasma 5-hydroxyindolacetic acid (5hiaa) values in patients with small-intestine neuroendocrine tumors

Conditions: Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)

Summary: urinary measure of 5-hydroxyindolacetic acid (5hiaa) is an important marker for the diagnosis and follow-up of patients with small-intestine neuroendocrine tumors. although this marker has good specificity, its sensitivity is moderate and its dosage is constraining, since it requires urine collection over 2-3 days and specific diet. preliminary data suggested that overnight 5hiaa value may be representative of 24-hour 5hiaa value, and that plasma 5hiaa dosage could be a valuable alternative to urine 5hiaa dosage. the main objective of this study is to compare sensitivity and specificity of overnight 5hiaa value, 24-hour 5hiaa value and plasma 5hiaa value, in patients with small-intestine neuroendocrine tumors.

this study primarily aims at comparing the sensitivity and specificity of overnight 5hiaa value, 24-hour 5hiaa value and plasma 5hiaa value, in patients with small-intestine neuroendocrine tumors. secondary objectives include the correlation of 5hiaa values with chromogranin a, carcinoid syndrome and tumor burden and the evaluation of the compliance to the diet and its correlation with 5hiaa values. the study group will include patients with proven neuroendocrine tumors of various stages and functioning syndrome profile. a control group will be constituted with subjects having irritable bowel syndrome, in which a neuroendocrine tumor is ruled out. after providing informed consent, patients fitting with inclusion criteria will be included in the study. patients will have to follow a specific diet, and interrupt/avoid certain medication, during the 2 days before and the 2 days during the sampling period. whole urine samples will be collected during 2 consecutive days, in 4 parts (day1, night 1, day 2, night 2). blood samples will be collected at the morning of days 2 and 3. observance with diet and drug restriction will be evaluated at the morning of day 3.

Eligibility criteria:
inclusion criteria: * histologically proven small-intestine neuroendocrine tumors, at initial diagnosis or during the follow-up * irritable bowel syndrome, diagnosed following rome iii criteria, who had an ileo-colonoscopy and an abdominal ct-scan within the 12 last months * age \> 18 years * no antitumor treatment within the last three months excepted somatostatin analogs * ability of understanding and approving the study protocol and of providing written consent * affiliation to the french health social system exclusion criteria * small-intestine neuroendocrine tumor in remission (no detectable disease) * other malignancies than small-intestine neuroendocrine tumors (excepted if in remission for more than 2 years) * kidney insufficiency (mdrd \< 60/min) * urinary incontinency or inability to collect urines * any antitumor treatment within the last three months excepted somatostatin analogs * inability to interrupt treatments interfering with 5hiaa dosage * pregnancy * patients under law protection
role of cord blood hormones and epinephrine in the development of transient tachypnea of the newborn

Conditions: Wet Lung

Summary: in this prospective, cross-sectional study, the aim was to investigate the possible role of cord stress hormones; adrenocorticotropic hormone (acth), cortisol, epinephrine, st3, st4, and thyroid-stimulating hormone (tsh) in the development of transient tachypnea of the newborn (ttn), via their modulatory effect on epithelial sodium channels and na-k-atpase.


Eligibility criteria:
inclusion criteria: * gestation age \> 34 weeks * c/s delivered infants * parental consent form signed exclusion criteria: * gestation age \< 34 weeks * maternal conditions that compromised fetal well-being (hypertensive disorder, diabetes, chorioamnionitis) * intrauterine growth retardation * congenital malformations * absence of parental consent

Keywords: fetal lung fluid pulmonary adaptation transient tachypnea of the newborn epinephrine stress hormones
buprenorphine/naloxone treatment for opioid dependence-experiment iii) - 3

Conditions: Heroin Dependence; Opioid-Related Disorders

Summary: the purpose of this study is to compare the clinical efficacy of the buprenorphine/naloxone combination tablet to methadone for opioid maintenance treatment.

s/a brief "summary for the public"

Eligibility criteria:
inclusion criteria: individuals must be at least 18 years of age, currently opioid dependent and meet fda criteria for narcotic maintenance treatment. co-morbid substance abuse or dependence disorders may also be present. individuals must be healthy despite drug dependency. exclusion criteria: individuals with evidence of an active diagnostic and statistical manual of mental disorders (dsm-iv) axis i psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Keywords: drug dependence
comparing imitation and stereotyped behaviors in autistic children: robots vs. human operators

Conditions: Autism; Autism Spectrum Disorder

Summary: virtual qt is a social robot designed to interact with humans in social and educational contexts. equipped with visual and vocal interfaces, the robot can recognize and respond to various human inputs, providing emotional support and social interaction. it uses facial expressions, gestures, and movements to communicate, encouraging engagement and supporting learning through playful and educational activities. its ergonomic design and interactive approach make it suitable for both clinical and educational settings. the aim of this study is to examine the effectiveness of the qtrobot in interventions for children with autism spectrum disorder (asd) and to assess whether children's attention and imitation are equally effective with the qtrobot compared to interacting with a human being. furthermore, the presence of significant differences between motor and expressive imitation, when interacting with the robot as opposed to a human interlocutor, will be investigated. a key aspect of this investigation is to assess whether the presence of the qtrobot can positively influence the repetitive or stereotyped behaviors exhibited by the children, compared to interaction with a person. additionally, to further understanding, the children's heart rate will be monitored through the use of a sensor that will allow to evaluate how heart rate affects performance outcomes during interaction with the qtrobot and with a human being. in this study, children will be recruited to take part in two separate sessions, both involving the same task. during the first session, the task will be carried out between the child and the human operator. subsequently, in the same task, the child will interact with the qt robot. throughout both task administrations, the child will wear a sensor to detect their heart rate. furthermore, all task sessions will be video-recorded to conduct subsequent video analysis and make notes on imitation behaviors and stereotypical actions relevant to the study.


Eligibility criteria:
inclusion criteria: * diagnosis of autism * qi ≥ 75 exclusion criteria: * motor deficits due to another clinical condition

Keywords: autism social robot imitation stereotypies
validity of viome's oral/throat cancer test

Conditions: Oral and Throat Cancer; Oropharyngeal Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma

Summary: a total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with oscc or opscc will be enrolled from either primary or secondary care centers in the u.s. clinicians will use viome collection kits to collect saliva samples from eligible patients.

this is a prospective, multi-center study. subjects with oscc or opscc will be enrolled from four primary and secondary care centers in the u.s. study samples will be collected by the clinicians at the study sites using viome saliva sample collection kits. patients will continue with their current health plan and confirm diagnosis following the standard of care of surgical biopsy with histology if needed. if a biopsy is performed, the result of the biopsy will be compared with the result of the viome kit. if no biopsy is performed, the viome test result will be compared with the physician's assessment based on clinical judgment. patients with a positive result from histology will not receive the results of the viome kit, and it will not play any part in the clinical management of the patients.

Eligibility criteria:
inclusion criteria: * signed and dated informed consent prior to any study-specific procedures are performed * willing and able to follow the study instructions, as described in the recruitment letter * adults (18 years old or older) * suspicion of oscc or opscc on clinical presentation by a clinician exclusion criteria: * pregnancy * use of fertility enhancing medications

Keywords: oscc opscc oral cancer throat cancer oral and throat cancer
study in letrozole combined with metronomic oral cyclophosphamide in elderly metastasis breast cancer patients

Conditions: Breast Neoplasms; Neoplasm Metastasis

Summary: this is a randomized clinical trial to investigate the efficacy of letrozole combined with metronomic oral cyclophosphamide in elderly metastasis breast cancer patients.


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic breast cancers patients with estrogen receptor positive and/or progesterone receptor positive; * elderly women (age ≥ 65years) * failure or relapse from standard chemotherapy or unfit for chemotherapy * measurable disease per response evaluation criteria in solid tumors(recist); * eastern cooperative oncology group (ecog) performance status of 0-2; * adequate bone marrow, liver and renal function; * estimated life expectancy of at least 3 months. exclusion criteria: * serious or uncontrolled concurrent medical illness * uncontrolled primary and metastatic brain tumor * history of second primary malignancies * having been enrolled in other clinical trials within a month
effect of longitudinal sleep monitoring on diagnosis and treatment decision in patients with suspected obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea (osa) is a highly prevalent sleep-disordered breathing disease, caused by recurrent episodes of partial or complete collapse of the upper airway during sleep, resulting in intermittent hypoxia, fragmented sleep, fluctuations in blood pressure, and increased sympathetic nervous system activity. a single-night sleep study (i.e. respiratory polygraphy or polysomnography) is currently considered to be the gold standard for diagnosing osa. however, recent studies suggest a significant intra-individual night-to-night variability of respiratory events, leading to the hypothesis that one single-night study might not reflect an accurate picture of the disease. part a: patients with suspected obstructive sleep apnea, referred to our clinic, undergo the regular diagnostic procedure recommended by the current guidelines. in addition to the in-hospital single-night sleep study, these patients will perform 14 nights of pulse-oximetry at home. by computing and analysing sensitivity and specificity of every additional night, the investigator will answer the questions how many nights of sleep monitoring by home oximetry are necessary to diagnose osa reliably, and how longitudinal sleep monitoring could reduce the number of false-negative and false- positive results compared to the in-hospital single-night study. part b: based on the patients' data of part a, the investigator will develop a questionnaire and present anonymized cases to experts in the field of sleep medicine. thereby, the investigator will evaluate if the additional information of repeated nocturnal pulse-oximetries changes the experts' decision making regarding diagnosis and treatment of osa. in a second step, the investigator will perform a classical delphi study with a panel of experts in sleep medicine to establish consensus on repeated sleep studies and how they should be used for diagnosis and treatment in patients with suspected osa.


Eligibility criteria:
inclusion criteria: * informed consent * suspected obstructive sleep apnea * ≥18 years old exclusion criteria: * suspected or diagnosed sleeping-disordered breathing other than osa * moribund or severe disease prohibiting protocol adherence especially copd gold iii-iv and heart failure nyha iii-iv * patients receiving oxygen therapy or home ventilation * continuous positive airway pressure treatment for osa at baseline * physical or intellectual impairment precluding informed consent or protocol adherence * pregnant patients

Keywords: night-to-night variability apnoea-hypopnoea index oxygen desaturation index pulse-oximetry
osteopathic manual treatment parkinson's disease and truncal dystonia

Conditions: Parkinson Disease; Dystonia; Autonomic Dysreflexia

Summary: this study will determine if posture and heart rate variability will significantly improve in parkinsons disease with camptocormia after osteopathic manual treatments dystonia.

this study will determine if posture and heart rate variability will significantly improve in parkinsons disease with camptocormia after receiving 8-weekly sessions of the osteopathic manual treatments for truncal flexion dystonia as measured by the distance of the external acoustic meatus from a plumb-line to lateral malleolus, spinal x ray, and heart rate variability.

Eligibility criteria:
inclusion criteria: * parkinson's disease; able to stand for three minutes or more exclusion criteria: * severe dementia, moderate or severe hallucinations and psychosis; unable to stand for three minutes

Keywords: manual therapy heart rate
paclitaxel in combination with carboplatin versus paclitaxel plus epirubicin in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: paclitaxel plus epirubicin in metastatic breast cancer is a recommended scheme in national comprehensive cancer network (nccn) guideline. paclitaxel in combination with carboplatin is also effective in metastatic breast cancer (mbc) in some clinical study with small sample.

a randomized prospective clinical trial of paclitaxel in combination with carboplatin versus paclitaxel plus epirubicin as first-line treatment in metastatic breast cancer. the primary endpoints of the study is progression free survival (pfs). the secondary endpoints are overall response rate (orr), overall survival (os) and safety.

Eligibility criteria:
inclusion criteria: * female ≥ 18 years old, ecog 0-2 or kps≥60, expected lifetime more than 12 weeks. exclusion criteria: * pregnancy, paclitaxel, platinum and anthracycline-based drugs' allergy, severe infection.
comparison of oral zaldiar with intravenous paracetamol and tramadol

Conditions: Pain

Summary: comparison of two different regimens of analgesia after inguinal hernia repair. first, is a classical intravenous protocol with paracetamol and tramadol. second is an oral protocol with zaldiar (combination of paracetamol and tramadol).

comparison of two different regimens of analgesia after inguinal hernia repair. first, is a classical intravenous protocol with paracetamol and tramadol. this is the classical approach. second is an oral protocol with zaldiar (combination of paracetamol and tramadol). this is the new approach.

Eligibility criteria:
inclusion criteria: * all patients incoming for inguinal hernia repair exclusion criteria: * preoperative abuse of analgesics